Indeed, cGAMP would be transferred via gap junctions to DCs, macrophages and non-tumor host cells, where STING activation will promote the production of immunostimulatory type I IFN (135) and therefore a good response to immunotherapy (146). This evidence concerns the gene STING1 and neoplasm.